While recent studies in animal models suggest that NLRP3 inhibitors might be useful for treating RA (33), our data suggest that combined targeting of CD64 and both NLRC4 and NLRP3 inflammasomes might be a useful synergistic strategy to reduce aberrant inflammatory responses in CD1c+ cDC, as well as other myeloid subsets, and prevent RA progression. This evidence concerns the gene NLRC4 and rheumatoid arthritis.